Quantcast

Latest Heart failure Stories

2014-05-19 12:34:04

European Society of Cardiology Serelaxin has neutral effect on diuretic response Poor diuretic response is associated with worse in-hospital and post-discharge clinical outcomes, results of the RELAX-AHF trial reveal. The study also found that serelaxin has a neutral effect on diuretic response. These novel data from the RELAX-AHF trial were presented by lead author Professor Adriaan A. Voors at the Heart Failure Congress 2014, held 17-20 May in Athens, Greece. The Congress is the...

2014-05-19 12:31:37

European Society of Cardiology Worsening symptoms and signs of heart failure in patients admitted to a hospital is a common sign of treatment failure Worsening symptoms and signs of heart failure (WHF) in patients admitted to a hospital is a common sign of treatment failure and can lead to long-term consequences for the patient, including longer length of hospitalization and a higher risk for readmission and death, according to a late-breaking study (RELAX-AHF, PROTECT) presented in...

2014-05-19 11:45:34

European Society of Cardiology Negative iron balance predicts survival in patients with acute heart failure, according to research presented for the first time today at the Heart Failure Congress 2014 in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology. Professor Ewa Jankowska, first author of the study, said: "Patients with acute heart failure have a major collapse in homeostasis. Iron is a key micronutrient...

2014-05-19 11:42:51

European Society of Cardiology Sleeping pills increase the risk of cardiovascular events in heart failure patients by 8-fold, according to research from Japan. The study was presented today at the Heart Failure Congress 2014, held 17-20 May in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology. Dr Masahiko Setoguchi said: "Sleeping problems are a frequent side effect of heart failure and it is common for...

2014-05-19 11:34:54

Johns Hopkins Medicine New animal studies by Johns Hopkins cardiovascular researchers strongly suggest that sildenafil, the erectile dysfunction drug sold as Viagra and now under consideration as a treatment for heart failure, affects males and females very differently. The results of their investigations in varied male and female mouse models of heart failure are so clear-cut, says lead scientist Eiki Takimoto, M.D., Ph.D., that physicians may need to take gender into consideration...

2014-05-16 23:02:49

Recent studies by the National Health Institute of Health show that Sleep apnea significantly increases your chances of developing the characteristics of hypertension which can lead to heart failure. Dr. Gorman explains. Tarzana, CA (PRWEB) May 16, 2014 Over 7 million people in the US suffer from heart failure each year. Recent studies by the National Institute of Health show that having sleep apnea significantly increases the chances of developing the characteristics of hypertension...

2014-05-16 23:00:57

American Heart Association Awards Mount Sinai Beth Israel Heart Failure Program a Get With The Guidelines®–Heart Failure Gold Quality Achievement Award New York, NY (PRWEB) May 16, 2014 Mount Sinai Beth Israel is the proud recipient of the 2014 American Heart Association’s Get With The Guidelines®–Heart Failure Gold Quality Achievement Award. It is one of only three hospitals in New York City to have earned the prestigious designation. The Gold level award recognizes...

2014-05-15 16:28:57

Takeda Emphasizes Continued Commitment to ACTOS and Patient Safety DEERFIELD, Ill., May 15, 2014 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced today that in the case of Whitlatch v. Takeda the jury found in favor of Takeda. The trial began on April 21 in the Circuit Court of Cook County, Illinois, before Judge Deborah Dooling and is the fifth ACTOS (pioglitazone HCl) case to reach trial. "We empathize with the Whitlatch family but agree with the verdict," said...

2014-05-15 08:33:06

Completes Enrollment in Phase 2b Clinical Trial of CLP-1001 for Heart Failure SUNNYVALE, Calif., May 15, 2014 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced the closing a $6.5 million tranche in a $15 million Series D financing. Existing investors CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds participated in the round. Sorbent also...

2014-05-13 23:01:45

Mount Sinai study reports the socioeconomic status of congestive heart failure patients does not influence hospital rankings for heart failure readmissions. New York, NY (PRWEB) May 13, 2014 A new report by Icahn School of Medicine at Mount Sinai, published in the journal Circulation: Cardiovascular Quality and Outcomes, shows the socioeconomic status of congestive heart failure patients does not influence hospital rankings for heart failure readmissions. In the study, researchers...


Latest Heart failure Reference Libraries

Circulation (journal)
2012-06-04 14:21:01

Circulation is a scientific journal published by Lippincott Williams & Wilkins on behalf of the American Heart Association. In 2008 the journal added six subspecialty publications: Circulation: Arrhythmia and Electrophysiology, Circulation: Heart Failure, Circulation: Cardiovascular Imaging, Circulation: Cardiovascular Interventions, Circulation: Cardiovascular Quality and Outcomes, and Circulation: Cardiovascular Genetics. Circulation publishes articles related to research in and the...

More Articles (1 articles) »
Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related